Phase Ib/II Study of the Safety and Efficacy of Combination Therapy with Multikinase VEGF Inhibitor Pazopanib and MEK Inhibitor Trametinib In Advanced Soft Tissue Sarcoma
暂无分享,去创建一个
F. Meric-Bernstam | R. Kurzrock | M. Zahurak | C. Meyer | J. Ludwig | K. Shaw | J. Roszik | R. Zinner | V. Subbiah | Nilofer Azad | A. O'Connor
[1] O. Merimsky,et al. Pazolimus: pazopanib plus sirolimus following progression on pazopanib, a retrospective case series analysis , 2016, BMC Cancer.
[2] César Serrano,et al. RAS/MAPK pathway hyperactivation determines poor prognosis in undifferentiated pleomorphic sarcomas , 2016, Cancer.
[3] D. Clark,et al. Trametinib with and without pazopanib has potent preclinical activity in thyroid cancer , 2015, Oncology reports.
[4] T. Alcindor. Response of refractory Ewing sarcoma to pazopanib , 2015, Acta oncologica.
[5] Robin L. Jones,et al. Clinical Activity of Pazopanib in Metastatic Extraosseous Ewing Sarcoma , 2015, Rare tumors.
[6] S. Matsumoto,et al. Differences in the responses to pazopanib and the prognoses of soft tissue sarcomas by their histological eligibility for the PALETTE study. , 2015, Japanese journal of clinical oncology.
[7] D. Gandara,et al. A randomised phase II trial of selumetinib vs selumetinib plus temsirolimus for soft-tissue sarcomas , 2015, British Journal of Cancer.
[8] Yuan Qi,et al. Clinical actionability enhanced through deep targeted sequencing of solid tumors. , 2015, Clinical chemistry.
[9] Yutaka Yamamoto,et al. Pazopanib for recurrent extraosseous Ewing's sarcoma of the retroperitoneum , 2014, International journal of urology : official journal of the Japanese Urological Association.
[10] W. Weiss,et al. It takes two to tango: Dual inhibition of PI3K and MAPK in rhabdomyosarcoma. , 2013, Clinical cancer research : an official journal of the American Association for Cancer Research.
[11] Khin Thway,et al. Dual Blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) Pathways Synergistically Inhibits Rhabdomyosarcoma Cell Growth In Vitro and In Vivo , 2013, Clinical Cancer Research.
[12] F. Peale,et al. Oncogenic RAS pathway activation promotes resistance to anti-VEGF therapy through G-CSF–induced neutrophil recruitment , 2013, Proceedings of the National Academy of Sciences.
[13] Tae-Min Kim,et al. Overcoming evasive resistance from vascular endothelial growth factor a inhibition in sarcomas by genetic or pharmacologic targeting of hypoxia-inducible factor 1α , 2012, International journal of cancer.
[14] K. Horiuchi,et al. A novel multi‐kinase inhibitor pazopanib suppresses growth of synovial sarcoma cells through inhibition of the PI3K‐AKT pathway , 2012, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.
[15] J. Utikal,et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. , 2012, The New England journal of medicine.
[16] Dirk Schadendorf,et al. Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group , 2012 .
[17] R. Kurzrock,et al. Ewing's sarcoma: overcoming the therapeutic plateau. , 2012, Discovery medicine.
[18] J. Blay,et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial , 2012, The Lancet.
[19] Benjamin E. Gross,et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.
[20] Francis Y. Lee,et al. MAPK/ERK Signaling in Osteosarcomas, Ewing Sarcomas and Chondrosarcomas: Therapeutic Implications and Future Directions , 2012, Sarcoma.
[21] R. Kurzrock,et al. Phase 1 clinical trials for sarcomas: the cutting edge , 2011, Current opinion in oncology.
[22] Laurence Doyle,et al. Targeted Morphoproteomic Profiling of Ewing's Sarcoma Treated with Insulin-Like Growth Factor 1 Receptor (IGF1R) Inhibitors: Response/Resistance Signatures , 2011, PloS one.
[23] V. Subbiah,et al. Targeted Therapy of Ewing's Sarcoma , 2010, Sarcoma.
[24] A. Lazar,et al. Neoadjuvant treatment of soft‐tissue sarcoma: A multimodality approach , 2010, Journal of surgical oncology.
[25] C. Dominici,et al. RAS signaling dysregulation in human embryonal Rhabdomyosarcoma , 2009, Genes, chromosomes & cancer.
[26] A. Lazar,et al. Ewing’s Sarcoma: Standard and Experimental Treatment Options , 2009, Current treatment options in oncology.
[27] Lori Minasian,et al. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] S. Singer,et al. Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells , 2008, Molecular Cancer Therapeutics.